Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy

摘要: The use of dendritic cells (DC) in cancer immunotherapy is based on their potent abilities to present antigens, so they can act as 'natural adjuvants' enhance immunogenicity tumor antigens and stimulate specific cytotoxic T-cells. Large amounts DC be generated from bone marrow, neonatal cord blood, peripheral blood CD34(+) hematopoietic stem cells, or monocytes. then pulsed with re-infused. In vitro, antigen-pulsed allogeneic T-cell proliferation induction autologous T-cells; vivo, the inhibit growth tumors protect hosts (i.e. mice) development inoculated tumors. results preliminary clinical trials have shown that vaccines are safe elicit immune responses; however, rates responses low. It has become quite clear one key reason for unsatisfactory tumor-induced immunosuppression. Among factors contributing this type immunosuppression populations regulatory including: T-regulatory (T(reg)) myeloid-derived suppressor (MDSC), tumor-associated macrophages (TAM), expressing 2,3-dioxygenase indoleamine (IDO-DC). This review presents an overview current understanding about most research efforts directed overcome immunosuppressive activity due microenvironment.